Why Self-Pour Taprooms & Technology are the Future for Craft Beer

 

Craft beer is having its moment, one that shows no signs of stopping. While beer volume sales were down (albeit only one percent) in 2018, craft beer sales hiked up almost four percent, with a craft beer market of $27 billion.

This is giving room for taprooms to reach their customers in more unique ways; creating a new experience for drinkers to try these brews was the catalyst behind the development of Navigator Taproom, a self-pour beer and wine taproom in Chicago. On today’s Food & Bevarage Podcast, we sat down with Tim Enarson, co-founder of Navigator, to dissect his story and find the best practices for opening a self-pour taproom.

“It took about three years to launch, and we actually started with the idea to open a brewery. However, the market was saturated in Chicago, which is home to about 170 breweries, so we decided to do something different,” Enarson said.

What makes their taproom so unique is the self-pour concept, which wouldn’t have been possible with the technology behind it: PourMyBeer software. The software and setup allow visitors to use an RFID card to track the beverages they try, then they are free to explore and pour. “The technology offered by PourMyBeer really helped us envision a way to showcase all the amazing beers in Chicago and from around the world in a different way. It’s not the typical American bar experience; it’s a bit more European,” Enarson said.

The demand for craft beer has accelerated in the last decade, but Enarson pointed out that its roots go back much further. “Craft beer was actually very big pre-prohibition. Then when alcohol became illegal, only the biggest beer companies could survive. It very much set the U.S. back in terms of quality craft beer. Now it’s like the second coming with craft beer being highly sought-after,” he said.

Discover more about Tim’s story and their unique business model, supported by software like PourMyBeer’s, by giving this podcast a listen.

For the latest news, videos, and podcasts in the Food & Beverage Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @FoodMKSL
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More